All In Biotech

NDA 211527 · Galderma Labs Lp

Aklief

Trifarotene · Topical · Retinoid

Novel

Last checked: Nov 19, 2026Latest source record: Jul 19, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Oct 4, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

14

6 Phase 3, 0 recruiting

FAERS reports

183

43 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 16, 2024.

AKLIEF Cream is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. AKLIEF Cream is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. ( 1 )

Mechanism: Trifarotene is an agonist of retinoic acid receptors (RAR), with particular activity at the gamma subtype of RAR. Stimulation of RAR results in modulation of target genes which are associated with various processes, including cell differentiation and mediation of inflammation. The exact process by which trifarotene ameliorates acne is unknown.

Therapeutic areas: Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 4, 2019 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
1 products under this application
  • AKLIEF · TRIFAROTENE 0.005% · CREAM, TOPICAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Trifarotene" as an intervention, any sponsor and status, largest first.

All 14 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • erythema28
  • acne17
  • skin burning sensation17
  • urinary retention16
  • dry skin15
  • mydriasis15
  • skin exfoliation14
  • skin irritation13
  • off label use12
  • drug ineffective11
  • vision blurred10
  • pain of skin9

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20171
202026
202141
202220
202342
202421
202518
202614

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Aklief (Trifarotene)

2024 spending

$260K

Beneficiaries

186

373 claims

Per beneficiary

$1,395

$15.18 per unit

View as table
YearSpending
2020$51,447
2021$149,786
2022$178,334
2023$197,712
2024$259,556

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 8 on PubMed

Sponsor: Galderma Labs Lp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.